Literature DB >> 33718110

Impact of Graft Weight Change During Perfusion on Hepatocellular Carcinoma Recurrence After Living Donor Liver Transplantation.

Jong Man Kim1, Young Jae Chung1, Sangjin Kim1, Jinsoo Rhu1, Gyu-Seong Choi1, Jae-Won Joh1.   

Abstract

BACKGROUNDS: Inadequate liver volume and weight is a major source of morbidity and mortality after adult living donor liver transplantation (LDLT). The purpose of our study was to investigate HCC recurrence, graft failure, and patient survival according to change in right liver graft weight after histidine-tryptophan-ketoglutarate (HTK) solution perfusion in LDLT.
METHODS: Two hundred twenty-eight patients underwent LDLT between 2013 and 2017. We calculated the change in graft weight by subtracting pre-perfusion graft weight from post-perfusion graft weight. Patients with increased graft weight were defined as the positive group, and patients with decreased graft weight were defined as the negative group.
RESULTS: After excluding patients who did not meet study criteria, 148 patients underwent right or extended right hepatectomy. The negative group included 89 patients (60.1%), and the positive group included 59 patients (39.9%). Median graft weight change was -28 g (range; -132-0 g) in the negative group and 21 g (range; 1-63 g) in the positive group (P<0.001). Median hospitalization time was longer for the positive group than the negative group (27 days vs. 23 days; P=0.048). There were no statistical differences in tumor characteristics, postoperative complications, early allograft dysfunction, or acute rejection between the two groups. Disease-free survival, death-censored graft survival, and patient survival were lower in the positive group than the negative group. Additionally, the positive group showed strong association with HCC recurrence, death-censored graft survival, and patient survival in multivariate analysis.
CONCLUSION: This study suggests that positive graft weight change during HTK solution perfusion indicates poor prognosis in LDLT.
Copyright © 2021 Kim, Chung, Kim, Rhu, Choi and Joh.

Entities:  

Keywords:  hepatocellular carcinoma; living donors; outcomes; partial liver graft; perfusion

Year:  2021        PMID: 33718110      PMCID: PMC7945034          DOI: 10.3389/fonc.2020.609844

Source DB:  PubMed          Journal:  Front Oncol        ISSN: 2234-943X            Impact factor:   6.244


  21 in total

1.  Weight increase during machine perfusion may be an indicator of organ and in particular, vascular damage.

Authors:  C H Wilson; M A Gok; B K Shenton; S Balupuri; A J Gupta; J Asher; D Talbot
Journal:  Ann Transplant       Date:  2004       Impact factor: 1.530

2.  Living donor right liver lobes: preoperative CT volumetric measurement for calculation of intraoperative weight and volume.

Authors:  Arne-Jörn Lemke; Martin Julius Brinkmann; Thomas Schott; Stefan Markus Niehues; Utz Settmacher; Peter Neuhaus; Roland Felix
Journal:  Radiology       Date:  2006-07-25       Impact factor: 11.105

3.  ABO-incompatible Living Donor Liver Transplantation With Rituximab and Total Plasma Exchange Does Not Increase Hepatocellular Carcinoma Recurrence.

Authors:  Jong Man Kim; Choon Hyuck David Kwon; Jae-Won Joh; Sangbin Han; Jeejin Yoo; Kyunga Kim; Dong Hyun Sinn; Gyu-Seong Choi; David A Gerber; Hiroto Egawa; Suk-Koo Lee
Journal:  Transplantation       Date:  2018-10       Impact factor: 4.939

Review 4.  Systematic review of preservation solutions for allografts for liver transplantation based on a network meta-analysis.

Authors:  Fengying Rao; Jian Yang; Cheng Gong; Rong Huang; Qi Wang; Jun Shen
Journal:  Int J Surg       Date:  2018-04-21       Impact factor: 6.071

Review 5.  Predictive factors of short term outcome after liver transplantation: A review.

Authors:  Giuliano Bolondi; Federico Mocchegiani; Roberto Montalti; Daniele Nicolini; Marco Vivarelli; Lesley De Pietri
Journal:  World J Gastroenterol       Date:  2016-07-14       Impact factor: 5.742

6.  The significance of acute phase small-for-size graft injury on tumor growth and invasiveness after liver transplantation.

Authors:  Kwan Man; Chung Mau Lo; Jiang Wei Xiao; Kevin T Ng; Bai Shun Sun; Irene O Ng; Qiao Cheng; Chris K Sun; Sheung Tat Fan
Journal:  Ann Surg       Date:  2008-06       Impact factor: 12.969

7.  Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography.

Authors:  Ryota Masuzaki; Ryosuke Tateishi; Haruhiko Yoshida; Eriko Goto; Takahisa Sato; Takamasa Ohki; Jun Imamura; Tadashi Goto; Fumihiko Kanai; Naoya Kato; Hitoshi Ikeda; Shuichiro Shiina; Takao Kawabe; Masao Omata
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

Review 8.  Immunologic strategies and outcomes in ABO-incompatible living donor liver transplantation.

Authors:  Jongwook Oh; Jong Man Kim
Journal:  Clin Mol Hepatol       Date:  2019-03-26

Review 9.  Liver immunology and its role in inflammation and homeostasis.

Authors:  Mark W Robinson; Cathal Harmon; Cliona O'Farrelly
Journal:  Cell Mol Immunol       Date:  2016-04-11       Impact factor: 11.530

Review 10.  Liver graft preservation methods during cold ischemia phase and normothermic machine perfusion.

Authors:  Konstantin Y Tchilikidi
Journal:  World J Gastrointest Surg       Date:  2019-03-27
View more
  1 in total

Review 1.  Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models.

Authors:  Wojciech Andrzej Straś; Dariusz Wasiak; Beata Łągiewska; Olga Tronina; Marta Hreńczuk; Joanna Gotlib; Wojciech Lisik; Piotr Małkowski
Journal:  Ann Transplant       Date:  2022-01-26       Impact factor: 1.530

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.